Ophthalmic Business News

CMS assigned a permanent, product-specific J-code for Syfovre for the treatment of geographic atrophy secondary to age-related macular degeneration, according to a press release from Apellis Pharmaceuticals.

Izervay met its primary objective of slowing geographic atrophy growth compared with sham at 24 months in the phase 3 GATHER2 clinical trial, according to a press release from Astellas Pharma.

Bausch + Lomb has announced the U.S. commercial launch of Miebo, a perfluorohexyloctane ophthalmic solution designed to treat signs and symptoms of dry eye disease by directly targeting tear evaporation.

Alex Gorsky, the former chairman and CEO of Johnson & Johnson, has been elected to Neurotech’s board as lead director, according to a press release.

Mergers and acquisitions have come to private practice medicine during the last 5 years — and in a big way. It would be difficult to find a physician of any specialty in any U.S. location who is not aware of this trend.

Novartis is discontinuing the development of GT005 for the treatment of geographic atrophy secondary to dry age-related macular degeneration, according to a press release from Syncona.

As physicians age, they should consider the reallocation of their assets into increasingly conservative investments to best limit their exposure to loss.

The FDA issued a complete response letter noting its rejection of the biologics license application for ONS-5010 for the treatment of wet age-related macular degeneration, according to a press release from Outlook Therapeutics.

Apellis announced a corporate reconstructing to drive growth of Syfovre and Empaveli, which will include cost-cutting initiatives expected to save the company up to $300 million through 2024, according to a press release.

MARCO ISLAND, Fla. — In this Healio Video Perspective, Lori Tierney, MBA, Johnson & Johnson Vision president of Americas, discusses leadership lessons based on openness to new spaces, diversity, equity and inclusion.